Dilated Cardiomyopathy


Aastrom To Refocus Research On Dilated Cardiomyopathy, Cut Staff

Aastrom Biosciences Inc., a developer of patient-specific expanded multicellular therapies for the treatment of severe chronic diseases, announced a strategic change in its research and development programs to focus on the clinical development of its lead product, ixmyelocel-T, for the treatment of dilated cardiomyopathy.

WWJ Newsradio 950–03/27/2013